{
    "success": true,
    "data": {
        "id": 1688976,
        "msgid": "prodias-business-strategy-shifts-clinic-expansion-adjusted-to-market-absorption-capacity-1776685857",
        "date": "2026-04-20 17:40:51",
        "title": "Prodia's Business Strategy Shifts, Clinic Expansion Adjusted to Market Absorption Capacity",
        "author": "Intan Pratiwi",
        "source": "REPUBLIKA",
        "tags": "",
        "topic": "Business",
        "summary": "PT Prodia Widyahusada Tbk (PRDA) is shifting its business strategy by adopting a more selective approach to expanding its clinics, focusing on market absorption and the availability of medical personnel rather than aggressive growth. The company is cautiously introducing advanced services like stem cell therapy, which targets degenerative diseases in the elderly, while highlighting the high costs associated with skilled doctors as the primary investment challenge. This measured expansion, including a recent acquisition of a stake in a stem cell firm, aims to manage risks and ensure quality in Indonesia's evolving high-tech healthcare sector.",
        "content": "<p>PT Prodia Widyahusada Tbk (PRDA) is beginning to change the direction\nof its business strategy. The company is no longer aggressively adding\nthe number of clinics but is instead more selective, taking into account\nmarket absorption capacity and the readiness of medical personnel.<\/p>\n<p>Prodia CEO Dewi Muliaty stated that the launch of new services,\nincluding stem cell-based therapy, cannot be done hastily.<\/p>\n<p>\u201cEvery time we open something new, there must be market absorption.\nWe can\u2019t just open it right away,\u201d she said in an official statement\nquoted on Monday (20\/4\/2026).<\/p>\n<p>According to her, this approach differs from the expansion of\nlaboratory services, which has so far been volume-based. For\nhigh-technology health services, the market is considered still limited,\nthus requiring more careful calculations.<\/p>\n<p>In addition to market factors, the availability of medical personnel\nis the main challenge. Prodia assesses that the biggest investment is\nnot in infrastructure but in the expertise of doctors handling those\nservices.<\/p>\n<p>\u201cThe most expensive investment is doctors. Their expertise is what\u2019s\nexpensive,\u201d Dewi said.<\/p>\n<p>Therefore, the launch of new services will greatly depend on the\nreadiness of human resources. The company ensures that every service is\nsupported by doctors with competencies and vision that align to maintain\nquality.<\/p>\n<p>Currently, stem cell therapy services are only available at the\nProdia Senior Health Centre in Jakarta. This service targets\ndegenerative diseases such as osteoarthritis and osteoporosis, which are\ncommonly experienced by the elderly.<\/p>\n<p>Prodia views the potential market for technology-based health\nservices, including regenerative therapy, as still open. However, its\ndevelopment is carried out gradually and not in the form of mass\nexpansion.<\/p>\n<p>This step is also part of the company\u2019s strategy in managing business\nrisks. Amid high costs and a market that is not yet broad, expansion\nthat is too rapid is considered potentially to pressure performance.<\/p>\n<p>As part of business strengthening, Prodia previously acquired a 30\npercent stake in PT Prodia StemCell Indonesia (ProSTEM) worth Rp33\nbillion in 2025. This collaboration is aimed at developing\nbiotechnology-based health services and precision medicine.<\/p>\n<p>Going forward, Prodia remains open to opportunities for service\nexpansion to major cities. However, such steps will be carried out\nselectively, considering market readiness and medical personnel.<\/p>\n<p>For the public, this strategy change reflects a shift in the health\nservices business. Access to advanced services like stem cell therapy is\nindeed starting to become available, but it cannot yet be expanded\nquickly due to cost factors and limitations in expert personnel.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/prodias-business-strategy-shifts-clinic-expansion-adjusted-to-market-absorption-capacity-1776685857",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}